Heat Biologics (HTBX) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. PPG

Go back to Heat Biologics (HTBX) Tops Q2 EPS by 10c

Noble Financial Sees Multiple Readouts for Heat Biologics (HTBX) by YE16; Maintains 'Buy' Rating

August 17, 2016 11:25 AM EDT

Noble Financial affirms Heat Biologics, Inc. (HTBX) with a Buy rating and $8 price target following recent Q2 results.

Analyst Kumaraguru Raja sees multiple readouts for Heat Bio by the end of the year. Key points include:

Potential candidate for acquisition or collaboration. ImPACT based clinical programs, HS-410 in non-muscle invasive bladder cancer (NMIBC), and... More

Roth Capital Keeps Heat Biologics (HTBX) at 'Buy' at Q4 Inflection Points Near

August 16, 2016 10:01 AM EDT

Roth Capital affirms Heat Biologics (Nasdaq: HTBX) at Buy with a price target of $2.75 following Q2 results issued on Monday.

Analyst Joseph Pantgninis noted that the company is moving quickly towards inflection points slated for Q416. The analyst commented:

Heat expects to report top-line data in 4Q16 for its Phase II trial evaluating HS-410 for the treatment of non-muscle invasive bladder cancer (NMIBC) and its Phase Ib trial evaluating HS-110 in... More